Drug Trial Radar · NCT00355862
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Jul 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
525
Actual
Start
Jan 2006
Primary completion
Apr 2009
Study completion May 2014
Sponsor
- Lead sponsor
- University of RegensburgAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC recurrence-free patient survival.
Conditions
- Hepatocellular Carcinoma
Interventions
CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)Drug
center specific therapeutic regimen without mTOR inhibition
SirolimusDrug
Sirolimus based immunosuppression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence free survivalTime frame: 5 year follow up after last patient in
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Regensburg University
Regensburg, Bavaria, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.